Clinical Trials Browser

Phase 2 × Colonic Neoplasms × anlotinib × Clear all

NCT04777162 2021-03-04

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Phase 2 Unknown

Gastrointestinal

Colonic Neoplasms, Stomach Neoplasms